Abstract

BackgroundAssociations between D-dimer and outcomes of patients with acute coronary syndromes (ACS) remain controversial. This study aimed to investigate the prognostic value of D-dimer in ACS patients treated by percutaneous coronary intervention (PCI).MethodsIn this observational study, 3972 consecutive patients with ACS treated by PCI were retrospectively recruited. The X-tile program was used to determine the optimal D-dimer thresholds for risk stratifications. Cox regression with multiple adjustments was used for outcome analysis. Restricted cubic spline (RCS) analysis was performed to assess the dose-response association between D-dimer and outcomes. The C-index was calculated to evaluate the additional prognostic value of D-dimer when added to clinical risk factors and commonly used clinical risk scores, with internal validations using bootstrapping methods. The primary outcome was all-cause death.ResultsDuring a median follow-up of 720 days, 225 deaths occurred. Based on the thresholds generated by X-tile, ACS-PCI patients with median (420–1150 ng/mL, hazard ratio [HR]: 1.58, 95 % confidence interval [CI]: 1.14–2.20, P = 0.007) and high (≥ 1150 ng/mL, HR: 1.98, 95 % CI: 1.36–2.89, P < 0.001) levels of D-dimer showed substantially higher risk of death compared to those with low D-dimer (< 420 ng/mL). RCS analysis depicted a constant relation between D-dimer and various outcomes. The addition of D-dimer levels significantly improved risk predictions for all-cause death when combined with the fully adjusted models (C-index: 0.853 vs. 0.845, P difference = 0.021), the GRACE score (C-index: 0.826 vs. 0.814, P difference = 0.027), and the TIMI score (C-index: 0.804 vs. 0.776, P difference < 0.001). The predicted mortality at the median follow-up (two years) was 1.7 %, 5.2 %, and 10.9 % for patients with low, median, and high D-dimer, respectively, which was well matched with the observed mortality (low D-dimer group: 1.2 %, median D-dimer group: 5.2 %, and high D-dimer group: 12.6 %).ConclusionsFor ACS patients treated by PCI, D-dimer level was an independent predictor for adverse outcomes, and provided additional prognostic value when combined with clinical risk factors and risk scores. Risk stratifications based on D-dimer was plausible to differentiate ACS-PCI patients with higher risk of death.

Highlights

  • Associations between D-dimer and outcomes of patients with acute coronary syndromes (ACS) remain controversial

  • For ACS patients treated by percutaneous coronary intervention (PCI), D-dimer level was an independent predictor for adverse outcomes, and provided additional prognostic value when combined with clinical risk factors and risk scores

  • Risk stratifications based on D-dimer was plausible to differentiate ACS-PCI patients with higher risk of death

Read more

Summary

Introduction

Associations between D-dimer and outcomes of patients with acute coronary syndromes (ACS) remain controversial. The cut-off thresholds for risk stratifications have not yet been developed or validated, as most previous studies generally divide patients according to selected percentiles [3, 4, 12, 13] It is not clear whether the risk of adverse outcomes grow constantly along with the increase of D-dimer, since there is no study analyzing the dose-response association between D-dimer and outcomes. The prognostic value of D-dimer remains controversial in the context of acute coronary syndrome (ACS), as previous studies report huge variation regarding hazards associated with D-dimer elevation, and its value for improving risk predictions [12,13,14,15,16,17,18]. This study aimed to investigate the followings: (1) the association between D-dimer and adverse outcomes, (2) the optimal D-dimer cut-off thresholds for risk stratifications, and (3) whether Ddimer could improve the risk predictions when added to common clinical risk factors and commonly used clinical risk scores, in order to offer evidence for clinical applications of D-dimer in ACS patients

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call